Sorafenib sensitizes hepatocellular carcinoma cell to cisplatin via suppression of Wnt/β-catenin signaling

Molecular and Cellular Biochemistry

Volumn 381, Issue 1-2, 2013, Pages 139-144

  Wei, Yongpeng ^a   Shen, Ningjia ^a   Wang, Zhouchong ^a   Yang, Guangshun ^a   Yi, Bin ^a   Yang, Ning ^a   Qiu, Yinghe ^a   Lu, Junhua ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Chemoresistance; Cisplatin; Hepatocellular carcinoma; Sorafenib; Wnt catenin

Indexed keywords

BETA CATENIN; CISPLATIN; SORAFENIB; WNT PROTEIN; WNT3 PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG SENSITIZATION; FEMALE; GROWTH INHIBITION; HEPATOMA CELL; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; WNT SIGNALING PATHWAY;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LIVER NEOPLASMS; MICE; MICE, NUDE; NIACINAMIDE; PHENYLUREA COMPOUNDS; WNT SIGNALING PATHWAY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84882732900     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-013-1695-6     Document Type: Article

References (23)

1. El-Serag HB, Mason AC (1999) Rising incidence of hepatocel-lular carcinoma in the United States. N Engl J Med 340:745-750
2. Parkin DM, Pisani P, Ferlay J (1999) Global cancer statistics. CA Cancer J Clin 49(1):33-64
3. Kerr SH, Kerr DJ (2009) Novel treatments for hepatocellular cancer. Cancer Lett 286:114-120. doi:10.1016/j.canlet.2009. 07.001
4. Yamashita T, Nagano K, Kanasaki S, Maeda Y, Furuya T, Inoue M, Nabeshi H, Yoshikawa T, Yoshioka Y, Itoh N, Abe Y, Kamada H, Tsutsumi Y, Tsunoda S (2012) Annexin A4 is a possible biomarker for cisplatin susceptibility of malignant mesothelioma cells. Biochem Biophys Res Commun 421:140-144. doi:10. 1016/j.bbrc.2012.03.144
5. Zidar BL, Green S, Pierce HI, Roach RW, Balcerzak SP, Mili-tello L (1988) A phase II evaluation of cisplatin in unresectable diffuse malignant mesothelioma: a southwest oncology group study. Invest New Drugs 6:223-226
6. Zhang Y, Wei W, Cheng N, Wang K, Li B, Jiang X, Sun S (2012) Hepatitis C virus-induced upregulation of miR-155 promotes hepatocarcinogenesis by activating Wnt signaling. Hepatology. doi:10.1002/hep.25849
7. Colnot S, Decaens T, Niwa-Kawakita M, Godard C, Hamard G, Kahn A, Giovannini M, Perret C (2004) Liver-targeted disruption of Apc in mice activates beta-catenin signaling and leads to hepatocellular carcinomas. Proc Natl Acad Sci USA 101:17216-17221. doi:10.1073/pnas.0404761101
8. Gosepath EM, Eckstein N, Hamacher A, Servan K, von Jonqui-eres G, Lage H, Gyorffy B, Royer HD, Kassack MU (2008) Acquired cisplatin resistance in the head-neck cancer cell line Cal27 is associated with decreased DKK1 expression and can partially be reversed by overexpression of DKK1. Int J Cancer 123:2013-2019. doi:10.1002/ijc.23721
9. Su HY, Lai HC, Lin YW, Liu CY, Chen CK, Chou YC, Lin SP, Lin WC, Lee HY, Yu MH (2010) Epigenetic silencing of SFRP5 is related to malignant phenotype and chemoresistance of ovarian cancer through Wnt signaling pathway. Int J Cancer 127:555-567. doi:10.1002/ijc.25083
10. Kane RC, Farrell AT, Madabushi R, Booth B, Chattopadhyay S, Sridhara R, Justice R, Pazdur R (2009) Sorafenib for the treatment of unresectable hepatocellular carcinoma. Oncologist 14:95-100. doi:10.1634/theoncologist.2008- 0185
11. Bruix J, Raoul JL, Sherman M, Mazzaferro V, Bolondi L, Craxi A, Galle PR, Santoro A, Beaugrand M, Sangiovanni A, Porta C, Gerken G, Marrero JA, Nadel A, Shan M, Moscovici M, Voliotis D, Llovet JM (2012) Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol. doi:10.1016/j.jhep.2012.06.014
12. Xiao RZ, Chen Y, Wang LL, Ruan XX, He CM, Xiong MJ, Lin DJ (2011) Sorafenib induces apoptosis of U937 cells via inhibiting WNT signal pathway. Zhongguo Shi Yan Xue Ye Xue Za Zhi 19:353-357
13. Esaki T, Nakano S, Masumoto N, Fujishima H, Niho Y (1996) Schedule-dependent reversion of acquired cisplatin resistance by 5-fluorouracil in a newly established cisplatin-resistant HST-1 human squamous carcinoma cell line. Int J Cancer 65:479-484
14. Zhang Y, Wei W, Cheng N, Wang K, Li B, Jiang X, Sun S (2012) Hepatitis C virus-induced up-regulation of microRNA-155 promotes hepatocarcinogenesis by activating Wnt signaling. Hepa-tology 56:1631-1640. doi:10.1002/hep.25849
15. Kapinas K, Kessler CB, Ricks T, Gronowicz G, Delany AM (2010) miR-29 modulates WNT signaling in human osteoblasts through a positive feedback loop. J Biol Chem 285(33):25221-25231
16. Geng W, Ng KT, Sun CK, Yau WL, Liu XB, Cheng Q, Poon RT, Lo CM, Man K, Fan ST (2011) The role of proline rich tyrosine kinase 2 (Pyk2) on cisplatin resistance in hepatocellular carcinoma. PLoS One 6:e27362. doi:10.1371/journal. pone.0027362
17. Wang H, Tan G, Dong L, Cheng L, Li K, Wang Z, Luo H (2012) Circulating MiR-125b as a marker predicting chemoresistance in breast cancer. PLoS One 7:e34210. doi:10.1371/journal. pone.0034210
18. Nagai T, Arao T, Furuta K, Sakai K, Kudo K, Kaneda H, Tamura D, Aomatsu K, Kimura H, Fujita Y, Matsumoto K, Saijo N, Kudo M, Nishio K (2011) Sorafenib inhibits the hepatocyte growth factor-mediated epithelial mesenchymal transition in hepatocel-lular carcinoma. Mol Cancer Ther 10:169-177. doi:10.1158/1535- 7163.MCT-10-0544
19. Feng YX, Wang T, Deng YZ, Yang P, Li JJ, Guan DX, Yao F, Zhu YQ, Qin Y, Wang H, Li N, Wu MC, Wang HY, Wang XF, Cheng SQ, Xie D (2011) Sorafenib suppresses postsurgical recurrence and metastasis of hepatocellular carcinoma in an orthotopic mouse model. Hepatology 53:483-492. doi:10.1002/hep.24075
20. Kohga K, Takehara T, Tatsumi T, Ishida H, Miyagi T, Hosui A, Hayashi N (2010) Sorafenib inhibits the shedding of major his-tocompatibility complex class I-related chain A on hepatocellular carcinoma cells by down-regulating a disintegrin and metallo-proteinase 9. Hepatology 51:1264-1273. doi:10.1002/hep.23456
21. Blivet-Van Eggelpoel MJ, Chettouh H, Fartoux L, Aoudjehane L, Barbu V, Rey C, Priam S, Housset C, Rosmorduc O, Desbois-Mouthon C (2012) Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells. J Hepatol 57:108-115. doi:10.1016/j.jhep.2012. 02.019
22. Chen KF, Chen HL, Tai WT, Feng WC, Hsu CH, Chen PJ, Cheng AL (2011) Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells. J Pharmacol Exp Ther 337: 155-161. doi:10.1124/jpet.110.175786
23. Kuo TC, Lu HP, Chao CC (2011) The tyrosine kinase inhibitor sorafenib sensitizes hepatocellular carcinoma cells to taxol by suppressing the HURP protein. Biochem Pharmacol 82:184-194. doi:10.1016/j.bcp.2011.04.008